DEF: HilleVax, Inc. Announces 2025 Annual Meeting of Stockholders

HilleVax, Inc. will hold its annual meeting of stockholders virtually on June 23, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm.

Summary

• HilleVax, Inc. is holding its annual meeting of stockholders on June 23, 2025, at 12:00 p.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 25, 2025, are entitled to vote.
• The meeting will address the election of three Class III directors for a three-year term expiring at the 2028 annual meeting, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Stockholders can vote by proxy via the Internet, telephone, or mail, or electronically during the annual meeting.
• The board of directors recommends voting 'For' the election of Robert Hershberg, Jeryl Hilleman, and Aditya Kohli as directors, and 'For' the ratification of Ernst & Young LLP as the independent registered public accounting firm.
• The company had 50,141,064 shares of common stock outstanding as of the record date.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions. The sentiment is slightly positive due to the routine nature of the items and the company's adherence to corporate governance best practices.

Positives

• The virtual meeting format is designed for ease of stockholder access and participation.
• Stockholders have multiple options for voting, including online, telephone, and mail.
• The board of directors is actively engaged in risk oversight and corporate governance.
• The audit committee is comprised of independent directors with financial expertise.
• The company has a compensation recovery (clawback) policy in place.

Negatives

• The company is an emerging growth company and has elected to comply with scaled-down executive compensation disclosure requirements.
• The company is not required to conduct votes seeking approval, on an advisory basis, of the compensation of its named executive officers or the frequency with which votes must be conducted.

Risks

• Failure to achieve a quorum could delay the meeting.
• If stockholders fail to ratify the selection of Ernst & Young LLP, the audit committee will reconsider whether to retain that firm.
• The company's success depends on the skills and experience of its directors and executive officers.
• The company's insider trading compliance policy prohibits officers, directors and employees pledging our stock as collateral to secure loans and from engaging in hedging transactions, including zero-cost collars and forward sale contracts.

Future Outlook

The proxy statement outlines the matters to be considered and voted on at the 2025 annual meeting, focusing on the election of directors and the ratification of the company's independent auditor.

Management Comments

• Robert Hershberg, M.D., Ph.D., Chairman, President and Chief Executive Officer: 'Your continued support of and interest in HilleVax, Inc. are sincerely appreciated.'

Industry Context

As a biopharmaceutical company, HilleVax's annual meeting and corporate governance practices are standard for publicly traded companies in the healthcare sector. The election of directors and ratification of auditors are routine matters.

Comparison to Industry Standards

• Virtual annual meetings have become increasingly common among publicly traded companies, especially in the biotechnology sector, offering broader accessibility to stockholders.
• The director independence criteria and committee structures align with Nasdaq requirements and are typical for companies of HilleVax's size and stage.
• The compensation structure for executive officers and directors is generally consistent with industry benchmarks, considering the company's status as an emerging growth company.

Related Party Transactions

• License agreement and clinical manufacturing and supply agreement with Takeda Vaccines, Inc.
• Transitional services agreement with Takeda Vaccines, Inc.
• Indemnification agreements with directors and executive officers.

Stakeholder Impact

• Shareholders are asked to vote on key governance matters.
• The outcome of the votes will influence the composition of the board and the selection of the company's auditor.
• The company's corporate governance practices impact investor confidence and long-term value.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the annual meeting.
• Final voting results will be published in a current report on Form 8-K filed with the SEC.

Key Dates

Keywords

annual meeting, proxy statement, directors, Ernst & Young, stockholders, voting, governance, HilleVax